ToxIVIG Study - Effect of Immunoglobulins on Mortality in Children with Toxic Shock Syndrome

ToxIVIG Study - Effect of Immunoglobulins on Mortality in Children with Toxic Shock Syndrome - ToxIVIG

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034536

Enrollment

322

Registered

2024-06-25

Start date

2024-07-17

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A40.0

Interventions

Group 1: Timeframe: Admission between January 1, 2016, and December 31, 2023. Age at admission = 28 days and < 18 years Screening: ICD-10 codes A40.0, A41.0, A48.3, R57.2

Inclusion: all cases with A48.3 + all other cases clinically meeting inclusion criteria for TSS

Eligibility

Sex/Gender

All

Age

28 Days to 18 Years

Inclusion criteria

Inclusion criteria: Timeframe: Admission between January 1, 2016, and December 31, 2023. Age at admission = 28 days and < 18 years Screening: ICD-10 codes A40.0, A41.0, A48.3, R57.2; Inclusion: all cases with A48.3 + all other cases clinically meeting inclusion criteria for TSS

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Evaluation of the Effect of Intravenous Immunoglobulins on Mortality in Children with Toxic Shock Syndrome	—

Secondary

Measure	Time frame
Evaluation of the effect of intravenous immunoglobulins in children with toxic shock syndrome on outcomes other than mortality.	—

Countries

Germany

Contacts

Public ContactNora Bruns

Kinderklinik I, Universitätsmedizin Essen

nora.bruns@uk-essen.de+492017232251

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026